Chinese NASH-Focused Biotech Firm Sciwind Biosciences Raises $29M Series A Round

Login to View

Sciwind Biosciences, a Chinese drug research and development company for metabolic diseases, announced on Wednesday that it has raised a nearly RMB200 million (US$29.58 million) series A round of financing led by Beijing-based investment firm Legend Capital.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Read 2 Articles for Free with a Basic Account

Gain limited and restricted access to China Money Network.

Register Basic Account

Subscribe for an annual subscription!

Enjoy comprehensive and exclusive data you can't find elsewhere!

More Info

Subscribe and Pay Easily Online!

Already have an account or paid subscription? Log in